Department of Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA.
J Gastroenterol. 2019 Sep;54(9):763-773. doi: 10.1007/s00535-019-01599-1. Epub 2019 Jul 3.
The use of mesenchymal stem cells (MSC) for tissue repair has garnered much interest and has been evaluated in several disease settings. Recent evidence indicates that the beneficial effects observed with MSC-based therapy can be mediated through the paracrine release of extracellular vesicles and other soluble proteins or biologically active molecules, which collectively constitute the MSC secretome. In this concise overview, we highlight results from preclinical and other studies that demonstrate the therapeutic efficacy of the MSC secretome for diseases that are characterized by liver injury or fibrosis. The potential for the use of the MSC secretome as an acellular regenerative therapy and approaches for the isolation of a secretome product for therapeutic applications are highlighted. The use of the MSC secretome as an acellular therapeutic agent could provide several advantages over the use of cell-based therapies for liver diseases.
间充质干细胞(MSC)在组织修复中的应用引起了广泛关注,并在多种疾病情况下进行了评估。最近的证据表明,基于 MSC 的治疗的有益效果可以通过细胞外囊泡和其他可溶性蛋白或生物活性分子的旁分泌释放来介导,这些物质共同构成了 MSC 的分泌组。在这个简要的概述中,我们强调了来自临床前和其他研究的结果,这些结果证明了 MSC 分泌组在以肝损伤或纤维化为特征的疾病中的治疗功效。我们还强调了使用 MSC 分泌组作为无细胞再生治疗的潜力,以及用于治疗应用的分泌组产物的分离方法。与基于细胞的肝脏疾病治疗方法相比,使用 MSC 分泌组作为无细胞治疗剂可能具有多个优势。